Barinthus Biotherapeutics plc
BRNS
$0.7815
-$0.0415-5.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.97M | 14.97M | 0.00 | 334.00K | 802.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.97M | 14.97M | 0.00 | 334.00K | 802.00K |
| Cost of Revenue | 11.70M | 12.25M | 11.11M | 11.63M | 10.34M |
| Gross Profit | 3.27M | 2.72M | -11.11M | -11.29M | -9.53M |
| SG&A Expenses | 24.01M | 41.02M | 28.42M | 34.35M | 40.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -976.00K | -792.00K | -582.00K | -5.00K | -- |
| Total Operating Expenses | 60.90M | 77.70M | 68.72M | 77.24M | 81.52M |
| Operating Income | -45.93M | -62.73M | -68.72M | -76.91M | -80.71M |
| Income Before Tax | -61.23M | -58.75M | -65.33M | -73.34M | -76.52M |
| Income Tax Expenses | -44.00K | -867.00K | -1.47M | -2.60M | -3.08M |
| Earnings from Continuing Operations | -61.18 | -57.88 | -63.86 | -70.74 | -73.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 109.00K | 55.00K | 78.00K | 88.00K | 100.00K |
| Net Income | -61.07M | -57.83M | -63.79M | -70.66M | -73.35M |
| EBIT | -45.93M | -62.73M | -68.72M | -76.91M | -80.71M |
| EBITDA | -43.33M | -60.12M | -66.12M | -74.47M | -78.49M |
| EPS Basic | -1.55 | -1.49 | -1.65 | -1.83 | -1.91 |
| Normalized Basic EPS | -0.69 | -0.95 | -1.06 | -1.19 | -1.25 |
| EPS Diluted | -1.56 | -1.49 | -1.65 | -1.84 | -1.92 |
| Normalized Diluted EPS | -0.69 | -0.95 | -1.06 | -1.19 | -1.25 |
| Average Basic Shares Outstanding | 157.39M | 155.82M | 154.93M | 154.30M | 153.54M |
| Average Diluted Shares Outstanding | 157.39M | 155.82M | 154.93M | 154.30M | 153.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |